Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The complaint alleges that BioAge's announcement on December 6, 2024, regarding the discontinuation of the STRIDES Phase 2 trial was unexpected, as the company had previously promoted azelaprag's potential [2]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of March 10, 2025, to potentially be appointed as lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].
BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA